Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 1
2004 4
2005 4
2006 2
2007 8
2008 6
2009 12
2010 9
2011 12
2012 19
2013 19
2014 17
2015 28
2016 36
2017 27
2018 40
2019 35
2020 19
2021 34
2022 28
2023 15
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

330 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J, Fouqueray P, Quinslot D, Grouin JM, Kaku K. Dubourg J, et al. Among authors: kaku k. Diabetes Obes Metab. 2022 Apr;24(4):609-619. doi: 10.1111/dom.14613. Epub 2021 Dec 27. Diabetes Obes Metab. 2022. PMID: 34866306 Free PMC article. Clinical Trial.
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Ueki K, et al. Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi: 10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24. Lancet Diabetes Endocrinol. 2017. PMID: 29079252 Clinical Trial.
[Alogliptin].
Tanabe A, Kaku K. Tanabe A, et al. Among authors: kaku k. Nihon Rinsho. 2011 May;69(5):871-6. Nihon Rinsho. 2011. PMID: 21595274 Review. Japanese.
Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
Kimura T, Katakura Y, Shimoda M, Kawasaki F, Yamabe M, Tatsumi F, Matsuki M, Iwamoto Y, Anno T, Fushimi Y, Kamei S, Kimura Y, Nakanishi S, Mune T, Kaku K, Kaneto H; COMING study Group. Kimura T, et al. Among authors: kaku k. Diabetes Obes Metab. 2023 Dec;25(12):3632-3647. doi: 10.1111/dom.15258. Epub 2023 Aug 30. Diabetes Obes Metab. 2023. PMID: 37646192 Clinical Trial.
Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
Katakura Y, Shimoda M, Ohnishi M, Kusano T, Dan K, Isobe H, Wamata R, Iwamoto Y, Fushimi Y, Sanada J, Obata A, Kimura T, Tatsumi F, Nakanishi S, Mune T, Kaku K, Kaneto H. Katakura Y, et al. Among authors: kaku k. Nutr Metab Cardiovasc Dis. 2023 Jul;33(7):1444-1452. doi: 10.1016/j.numecd.2023.02.011. Epub 2023 Feb 21. Nutr Metab Cardiovasc Dis. 2023. PMID: 37246074 Free article.
Efficacy of voglibose in type 2 diabetes.
Kaku K. Kaku K. Expert Opin Pharmacother. 2014 Jun;15(8):1181-90. doi: 10.1517/14656566.2014.918956. Epub 2014 May 5. Expert Opin Pharmacother. 2014. PMID: 24798092 Review.
330 results